Celyad (CYAD) Gets a Buy Rating from William Blair


In a report released today, Raju Prasad from William Blair maintained a Buy rating on Celyad (CYAD). The company’s shares closed yesterday at $21.97.

According to TipRanks.com, Prasad is a 4-star analyst with an average return of 5.4% and a 43.8% success rate. Prasad covers the Healthcare sector, focusing on stocks such as Rocket Pharmaceuticals Inc, Global Blood Therapeutics, and Logicbio Therapeutics Inc.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Celyad with a $48.50 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $48.20 and a one-year low of $15.36. Currently, Celyad has an average volume of 8,959.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Celyad SA is a clinical-stage biopharmaceutical company, which engages in the identification and development of specialized cell-based therapies. Its products include cardiopoiesis platform, immuno-oncology, and medical devices. The company was founded by Michel Lussier and William Wijns on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts